Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer.

Abstract

Virtually all cases of cervical cancer and its precursor intra-epithelial lesions are a result of infection with one or other of a subset of genital human papillomaviruses (HPVs), suggesting that prevention of HPV infection by prophylactic vaccination would be a highly effective anticancer strategy. Two HPV L1 virus-like particle vaccines have been developed, a quadrivalent HPV16/18/6/11 product and a bivalent HPV16/18 product; both have been shown to be highly immunogenic with a good safety profile and 100% efficacy against HPV16/18-related high-grade cervical intra-epithelial neoplasia (CIN2/3), implying that they will be effective at preventing HPV16/18-related cervical cancer.

• Authors: M Stanley
• Journal: British journal of cancer (Br J Cancer) Vol. 96 Issue 9 Pg. 1320-3 (May 07 2007) ISSN: 0007-0920 [Print] England
• PMID: 17375045 (Publication Type: Journal Article, Review)

Chemical References

• Papillomavirus Vaccines

Topics

• Anus Neoplasms (prevention & control, virology)
• Developed Countries
• Developing Countries
• Female
• Humans
• Incidence
• Papillomavirus Infections (immunology, prevention & control)
• Papillomavirus Vaccines
• Uterine Cervical Neoplasms (epidemiology, prevention & control, virology)